ZEALAND PHARMA A/S ZLDPF overview

Company announcement – No. 17 / 2020 Zealand Pharma major shareholder announcement: Wellington Management Group LLP Copenhagen, April 6, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the receipt of the following major shareholder notification: From April 1, 2020, Wellington Management Group LLP indirectly hold a total of DKK...

Company announcement – No. 16 / 2020 Zealand Pharma’s Annual General Meeting 2020 Copenhagen, April 3, 2020 – Yesterday, Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), held its Annual General Meeting of 2020 at Zealand Pharma A/S, Sydmarken 11, DK-2860 Søborg, Denmark. At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's...

Company announcement – No. 15 / 2020 Zealand Pharma completes the acquisition of Valeritas Zealand Pharma (NASDAQ: ZEAL) has acquired Valeritas Holdings, Inc. (NASDAQ: VLRX), a U.S. based commercial-stage company for a cash purchase price of $23 million The marketed V-Go ® wearable insulin delivery device, 110 employees, all supporting systems, processes and the majority of established contracts, and a site in Marlborough, Massachusetts, are transferred to Zealand Pharma The purchase...

Company announcement – No. 14 / 2020 Zealand Pharma provides business update related to current COVID-19 situation Strong progress in discovery and clinical pipeline, with positive Phase 2 results and NDA filing for Dasiglucagon HypoPal ® Rescue Pen to the U.S. FDA in March Expansion of U.S. commercial infrastructure on-track to be ready for anticipated launch of Dasiglucagon HypoPal ® Rescue Pen Secured funding for continued operations with DKK 137 million through a private placement to...

Company announcement – No. 13 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, March 31, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby...

Company announcement – No. 13 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, March 31, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby...

Company announcement – No. 12 / 2020 Total number of shares and voting rights in Zealand Pharma at March 31, 2020 Copenhagen, March 31, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, announces the total number of shares and voting rights in the...

Press Release – No. 04 / 2020 Zealand Pharma submits New Drug Application to the U.S. Food and Drug Administration for the Dasiglucagon HypoPal ® Rescue Pen for treatment of severe hypoglycemia The Dasiglucagon HypoPal ® Rescue Pen New Drug Application represents a major milestone in Zealand Pharma’s efforts to bring life changing therapies to people with diabetes The submission encompasses three Phase 3 trials which met all primary and key secondary endpoints with a median time to...

Company announcement – No. 11 / 2020 Zealand Pharma completes subscription of New Ordinary Shares and registration of capital increase Copenhagen, March 31, 2020 – In reference to Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) company announcement 09/2020 published March 26, 2020, regarding a private placement and directed issue of 741,816 new shares of the company (the "New Ordinary Shares"), Zealand Pharma A/S ("Zealand") announces that it has today increased its...

Company announcement – No. 10 / 2020 Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery A subset of individuals who undergo gastric bypass bariatric surgery experience recurrent episodes of serious hypoglycemia after meals and no satisfactory treatments are available Single mini-doses of dasiglucagon effectively reduced time spent in hypoglycemia after meals in individuals who have undergone bariatric...

Company announcement – No. 09 / 2020 Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000 A total of 741,816 new shares (the "New Ordinary Shares") have been subscribed for with expected gross proceeds of approx. DKK 137,236,000. The private placement and directed share issue to a U.S. based investor follows recent positive developments in Zealand Pharma’s product pipeline. The additional funding will be used to continue...

Company announcement – No. 08 / 2020 Annual General Meeting of Zealand Pharma A/S: Measures in consequence of COVID-19 Copenhagen, March 24, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) announces the following measures applied to Zealand’s Annual General Meeting 2020 that is scheduled for April 2, 2020. Annual General Meeting of Zealand Pharma A/ S: Measures in consequence of COVID-19 The Danish government is continuously launching a series of new measures...

Company announcement – No. 07 / 2020 Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim Zealand Pharma regains the worldwide rights to the Amylin analog program including once-weekly lead molecule Boehringer Ingelheim will focus on the once-weekly GLP-1/glucagon analog BI 456906, which has also been licensed from Zealand Pharma and is advancing into Phase 2 development Zealand Pharma will decide on the next development steps for the Amylin analog program...

Company announcement – No. 06 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, March 20, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby...

Company announcement – No. 05 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, March 20, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 91,475 divided into 91,475 new shares with a nominal value of DKK 1 each. The...